mRNA therapeutics emerged as a major therapeutic modality following the extraordinary success of the Moderna and Pfizer-BioNTech COVID-19 vaccines, which demonstrated that synthetic mRNA could be manufactured at global scale, safely administered to billions of people, and effectively instruct human cells to produce disease-relevant proteins. The underlying technology, including nucleoside modifications to reduce innate immune activation (pioneered by Katalin Kariko and Drew Weissman, awarded the 2023 Nobel Prize in Physiology or Medicine), lipid nanoparticle delivery, and sequence optimization, has opened vast therapeutic possibilities beyond vaccines.
Moderna and BioNTech are advancing mRNA-based therapies across oncology, rare diseases, and infectious diseases. Moderna's personalized cancer vaccine program (mRNA-4157/V940, in partnership with Merck) uses individualized neoantigen mRNA to train each patient's immune system against their specific tumor. In the gene editing space, mRNA delivery of CRISPR-Cas9 components offers a transient expression window that may be safer than DNA-based delivery, as the editing machinery is present only long enough to make the desired edits before being degraded. Intellia Therapeutics uses lipid nanoparticle-encapsulated mRNA to deliver CRISPR components for its in vivo gene editing programs.
The manufacturing of mRNA therapeutics relies on cell-free enzymatic synthesis using in vitro transcription (IVT) reactions, a process amenable to rapid scale-up and quality control. This cell-free production method avoids the complexities of cell-based manufacturing, enabling faster development timelines and more flexible production scaling. Companies including Arcturus Therapeutics and CureVac are developing next-generation mRNA technologies with self-amplifying and circular RNA designs that extend the duration of protein expression. The convergence of mRNA technology with synthetic biology continues to expand, as engineered mRNA constructs incorporate regulatory elements, modified nucleotides, and novel delivery formulations designed using computational approaches.